Ticker

SHANGHAI, June 25, 2026 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that the Company will effectuate a 1-for-3 share consolidation of the Company's ordinary shares of US$0.248 par value each (the "Share Consolidation"). Beginning with the opening of…

SHANGHAI, June 4, 2026 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that the Company will effectuate a 1-for-31 share consolidation of the Company's ordinary shares of US$0.008 par value each (the "Share Consolidation"). Beginning with the opening of…

Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering PR Newswire SHANGHAI, May 29, 2026

SHANGHAI, May 29, 2026 /PRNewswire/ -- Zhongchao Inc. ("Zhongchao" or the "Company") (NASDAQ: ZCMD), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced the pricing of a best efforts public offering with gross proceeds to the Company expected to be approximately $5 million, before deducting placement agent fees and other estimated expenses…

Standard BioTools (NASDAQ: LAB - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability. Insider and Institutional Ownership 53.7% of Standard BioTools